CN102078297A - Method for preparing osmotic diuretic injection containing high oxygen or electrolyte - Google Patents
Method for preparing osmotic diuretic injection containing high oxygen or electrolyte Download PDFInfo
- Publication number
- CN102078297A CN102078297A CN2011100086884A CN201110008688A CN102078297A CN 102078297 A CN102078297 A CN 102078297A CN 2011100086884 A CN2011100086884 A CN 2011100086884A CN 201110008688 A CN201110008688 A CN 201110008688A CN 102078297 A CN102078297 A CN 102078297A
- Authority
- CN
- China
- Prior art keywords
- injection
- osmotic
- diuretic
- hyperoxia
- mannitol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses a method for preparing an osmotic diuretic injection containing high oxygen or electrolyte. The method is characterized by dissolving high-concentration oxygen in an osmotic diuretic injection to form a high oxygen osmotic diuretic injection, or dissolving osmotic diuretics with different weights in a lactated Ringers solution to form an osmotic diuretic compound electrolyte solution, or dissolving high-concentration oxygen in the osmotic diuretic compound electrolyte solution to form a high oxygen osmotic diuretic compound electrolyte solution. In addition to having the conventional dehydration effect, the osmotic diuretic injection can increase the content of blood oxygen and supplement the electrolyte lost due to dehydration through intravenous infusion, and plays important roles in alleviating electrolyte disturbance and ensuring oxygen supply to important visceral organs. The osmotic diuretic injection can be more safely and widely used for treating cerebral edema and reducing intracranial pressure and intraocular pressure, effectively lessens various complications, and has important clinical application value and wide social and economic benefits.
Description
Technical field
The invention belongs to medical use liquid series, relate to a kind of hyperoxia and electrolytical medical use liquid of containing, particularly a kind of preparation method that contains hyperoxia or electrolytical osmotic diuresis remover liquid injection.
Background technology
Osmotic diuretic is that a class is difficult for metabolic low molecular compound, forms hyperosmosis immediately in blood plasma, Glomerular filtrate and renal tubules chamber liquid after the intravenous injection, makes electrolyte in the TF diluted and concentration reduces, thereby makes renal tubules to water and Na
+, Cl
-, K
+, Ca
2+, Mg
2+Reduce with the heavily absorption of other solutes or stop and producing diuresis.Clinically be generally used for treating cerebral edema, reduce intracranial pressure, reduce intraocular pressure, also can be used for the prophylaxis of acute renal failure.Its main adverse reaction is: 1. the most commonly power and water is separated the matter disorder; 2. fast a large amount of infusions can cause that blood volume increases sharply, and produce dilutional hyponatremia, can cause heart failure; 3. highly ooze stimulation and can cause thrombophlebitis, tissue edema and cutaneous necrosis; 4. medicine also can allergy cause diseases such as erythra, urticaria, dyspnea, anaphylactic shock, dizziness, blurred vision; During the quick venoclysis of 5. unsuitable excessive heavy dose, the hyperosmosis of liquid can cause the damage of renal cells swelling in the renal tubules, causes hypourocrinia permeability nephropathy.
In order to guarantee the dehydrating effect of osmotic diuretic, reduce Na
+, Cl
-, K
+, Ca
2+, Mg
2+Lose etc. electrolytical, and increase when dewatering the important organ oxygen supply, the research that contains hyperoxia or electrolytical osmotic diuresis remover liquid injection has been become one of focus of this area concern, its research has important clinical application value and application prospects.
Summary of the invention
The objective of the invention is to, a kind of preparation method that contains hyperoxia or electrolytical osmotic diuresis remover liquid injection is provided.The injection of this method preparation can be used for the treatment of cerebral edema safer, widely, reduces intracranial pressure, reduce intraocular pressure, and effectively reduces the generation of various complication.
In order to realize above-mentioned task, the present invention takes following technical solution:
A kind of preparation method that contains hyperoxia and electrolytical osmotic diuresis remover liquid injection is characterized in that, may further comprise the steps at least:
(1) in infusion solutions is produced, makes biomedical electrolysis matter injection by the medical use liquid routine operation, as base fluid;
(2) saturating property diuretic powder is dissolved in the base fluid, makes osmotic diurtc composite electrolyte injection;
(3) osmotic diurtc composite electrolyte injection is inserted in the sealable container airtight, behind the negative-pressure vacuum with the pure O of 1.5～2.0 atmospheric medical aseptics
2Or and O
3Mist feed in the osmotic diurtc composite electrolyte injection; After partial pressure of oxygen reaches more than the 90kPa, behind pyrogen test, be prepared into the osmotic diurtc composite electrolyte injection that contains hyperoxia.
A kind of preparation method that contains electrolytical osmotic diuresis remover liquid injection is characterized in that, may further comprise the steps at least:
(1) in infusion solutions is produced, makes biomedical electrolysis matter injection by the medical use liquid routine operation, as base fluid;
(2) saturating property diuretic powder is dissolved in the base fluid, makes osmotic diurtc composite electrolyte injection.
Above-mentioned biomedical electrolysis matter injection is to contain calcium chloride 0.01～0.03g in every 100ml liquid, potassium chloride 0.01～0.05g, sodium chloride 0.2～0.8g, sodium lactate 0.1～0.5g.
Above-mentioned osmotic diuretic is mannitol, piracetam, aniracetam, 1,6-fructose diphosphate, sorbitol, carbamide, glycerol one of them, or be the compound recipe of the osmotic diuretic of above-mentioned different proportion.
Adopt hyperoxia or the electrolytical osmotic diuresis remover liquid injection of containing of the present invention, the liquid oxygen partial pressure value is greater than original more than 4 times behind the dissolved oxygen, clinical except having dehydration, can also improve the oxygen content of blood, replenish and lose, to alleviating electrolyte disturbance and guaranteeing that the important organ oxygen supply has important function because of dehydration causes electrolyte.
The specific embodiment
In order clearly to understand the present invention, the invention will be further described to provide specific embodiment below in conjunction with the inventor.
Calcium chloride, potassium chloride, sodium chloride and the sodium lactate of plan weight are dissolved in and make biomedical electrolysis matter solution in the medical distilled water; Again the osmotic diuretic of Different Weight is dissolved in and makes the osmotic diurtc compound electrolyte solution in the aforesaid liquid; Adopt the quick replacement of oxygen dissolved oxygen of physics and photochemistry technology then,, make the osmotic diurtc compound electrolyte solution that contains hyperoxia being dissolved in the osmotic diurtc compound electrolyte solution of oxygen high concentration.
Specifically preparation by the following method:
(1) at first by medical use liquid compound method and requirement, making lactated ringer's inj (among every 100ml, containing calcium chloride 0.02g, potassium chloride 0.03g, sodium chloride 0.6g, sodium lactate 0.31g) by the medical use liquid routine operation is base fluid;
(2) according to the preparation demand, take by weighing a certain amount of osmotic diuretic (mannitol, piracetam, aniracetam, 1,6-fructose diphosphate, sorbitol, carbamide, glycerol, or being the compound recipe composition of the osmotic diuretic of different proportion) powder is dissolved in base fluid slowly, promptly make osmotic diurtc composite electrolyte injection, clinically be used for cerebral edema, reduce treatments such as intracranial pressure, also can effectively alleviate the electrolyte disturbance that causes because of dehydration and diuresis;
(3) further with the osmotic diurtc composite electrolyte injection of step (2) preparation, insert in the sealable container airtight, behind the negative-pressure vacuum with the pure O of 1.5～2.0 atmospheric medical aseptics
2Or and O
3Mist feed osmotic diurtc composite electrolyte injection 30min, divide instrument to measure through QI and blood, when the partial pressure of oxygen in the injection reaches 90kPa(680mmHg) when above, promptly make the osmotic diurtc composite electrolyte injection that contains hyperoxia.
Below be the embodiment that the inventor provides, need to prove that these embodiment are some more excellent examples, the invention is not restricted to these embodiment.
Embodiment 1: the preparation of mannitol composite electrolyte injection:
(1) makes lactated ringer's inj (among every 100ml, containing calcium chloride 0.02g, potassium chloride 0.03g, sodium chloride 0.6g, sodium lactate 0.31g) as base fluid by the medical use liquid routine operation;
(2) 20.0g mannitol powder is dissolved in the 100ml lactated ringer's inj (base fluid), promptly makes 20% mannitol composite electrolyte injection;
(3) handle through sterilization, can supply the human body infusion behind the pyrogen test.
Embodiment 2: mannitol 1, and the preparation of 6-fructose diphosphate combined electrolysis injection:
(1) makes lactated ringer's inj (among every 100ml, containing calcium chloride 0.02g, potassium chloride 0.03g, sodium chloride 0.6g, sodium lactate 0.31g) by the medical use liquid routine operation;
(2) with 1 of the mannitol of 13.0g and 5.0g, 6-fructose diphosphate powder is dissolved in the 100ml lactated ringer's inj, promptly makes mannitol 1,6-fructose diphosphate combined electrolysis injection;
(3) handle through sterilization, can supply the human body infusion behind the pyrogen test.
In the step (2) of present embodiment, can use osmotic diuresis medicine piracetam, aniracetam, sorbitol, carbamide or glycerol displacement 1, the 6-fructose diphosphate, make mannitol piracetam combined electrolysis injection, mannitol aniracetam combined electrolysis injection, mannitol sorbitol combined electrolysis injection, mannitol carbamide combined electrolysis injection, mannite and glycerol combined electrolysis injection.
Embodiment 3: the preparation of hyperoxia mannitol piracetam combined electrolysis injection:
(1) makes lactated ringer's inj (among every 100ml, containing calcium chloride 0.02g, potassium chloride 0.03g, sodium chloride 0.6g, sodium lactate 0.31g) by the medical use liquid routine operation;
(2) mannitol of 13.0g and the piracetam powder of 5.0g are dissolved in the 100ml lactated ringer's inj, promptly make mannitol piracetam combined electrolysis injection;
(3) the mannitol piracetam combined electrolysis injection of step (2) being made is stored in the container of sealing airtight, behind the negative-pressure vacuum with the pure O of 1.5～2.0 atmospheric medical aseptics
2Or and O
3Mist feed (2) liquid 30min, divide instrument to measure through QI and blood, when the partial pressure of oxygen in the injection reaches 90kPa(680mmHg) when above, promptly make hyperoxia mannitol piracetam combined electrolysis injection;
(4) handle through sterilization, can supply the human body infusion behind the pyrogen test.
In the present embodiment, osmotic diuresis medicine piracetam can be replaced as 1,6-fructose diphosphate, aniracetam, sorbitol, carbamide or glycerol, can obtain qualified hyperoxia combined electrolysis injection according to step (3) then (is hyperoxia mannitol 1,6-fructose diphosphate combined electrolysis injection, hyperoxia mannitol aniracetam combined electrolysis injection, hyperoxia mannitol sorbitol combined electrolysis injection, hyperoxia mannitol carbamide combined electrolysis injection, hyperoxia glycerol combined electrolysis injection).
Embodiment 4: the preparation method of hyperoxia formula mannitol injection liquid:
(1) makes 20% formula mannitol injection liquid by the medical use liquid operating routine;
(2) 20% formula mannitol injection liquid is stored in the container of sealing airtight, behind the negative-pressure vacuum with the pure O of 1.5～2.0 atmospheric medical aseptics
2Or and O
3Mist feed 0% formula mannitol injection liquid, 30 min, divide instrument to measure through QI and blood, when the partial pressure of oxygen in the injection reaches 90kPa(680mmHg) when above, promptly make the hyperoxia formula mannitol injection liquid;
(3) handle through sterilization, can supply the human body infusion behind the pyrogen test.
The present invention all obtains sure experimental result through preliminary experiment repeatedly:
1. adopt the hyperoxia mannitol piracetam combined electrolysis injection of making of embodiment 3, hyperoxia mannitol 1,6-fructose diphosphate combined electrolysis injection, hyperoxia mannitol aniracetam combined electrolysis injection, hyperoxia mannitol sorbitol combined electrolysis injection, hyperoxia mannitol carbamide combined electrolysis injection, hyperoxia glycerol combined electrolysis injection, partial pressure of oxygen reach 93 ± 5.8kPa(706.8 ± 44.08mmHg);
2. the electrolyte of injection reaches predefined requirement, contains calcium chloride 0.02g, potassium chloride 0.03g, sodium chloride 0.6g, sodium lactate 0.31g among every 100ml;
3. good stability, December is deposited in the injection sealing, and partial pressure of oxygen does not have obvious change.Efficient liquid item chromatographic determination mannitol, 1, the electrolysis composition of 6-fructose diphosphate, piracetam, aniracetam, sorbitol, carbamide and each injection of glycerol does not have change, does not see that neoplasm generates yet;
4. using the scale-model investigation of middle cerebral artery occlusion focal cerebral ischemia shows, from intravenous injection hyperoxia mannitol piracetam combined electrolysis injection 30mL/kg(or hyperoxia mannitol 1,6-fructose diphosphate combined electrolysis injection 30mL/kg, hyperoxia mannitol aniracetam combined electrolysis injection 30mL/kg, hyperoxia mannitol sorbitol combined electrolysis injection 30mL/kg, hyperoxia mannitol carbamide combined electrolysis injection 30mL/kg, hyperoxia glycerol combined electrolysis injection 30mL/kg), diuretic effect is 2.8 times of dose,equivalent 20% mannitol, dehydrating effect is 1.3 times of dose,equivalent 20% mannitol, with obviously improving PaO
212-15 mmHg, and can effectively reduce the electrolyte disturbance that dehydration causes.Conclusion is a hyperoxia mannitol piracetam combined electrolysis injection (or hyperoxia mannitol 1,6-fructose diphosphate combined electrolysis injection, hyperoxia mannitol aniracetam combined electrolysis injection, hyperoxia mannitol sorbitol combined electrolysis injection, hyperoxia mannitol carbamide combined electrolysis injection, hyperoxia glycerol combined electrolysis injection) venoclysis, dehydration and diuretic effect significantly strengthen, and can effectively improve the oxygen content of blood and keep the body electrolyte balance, demonstrate good potential applicability in clinical practice and economy and society benefit.
Claims (6)
1. a preparation method that contains hyperoxia and electrolytical osmotic diuresis remover liquid injection is characterized in that, may further comprise the steps at least:
(1) in infusion solutions is produced, makes biomedical electrolysis matter injection by the medical use liquid routine operation, as base fluid;
(2) saturating property diuretic powder is dissolved in the base fluid, makes osmotic diurtc composite electrolyte injection;
(3) osmotic diurtc composite electrolyte injection is inserted in the sealable container airtight, behind the negative-pressure vacuum with the pure O of 1.5～2.0 atmospheric medical aseptics
2Or and O
3Mist feed in the osmotic diurtc composite electrolyte injection; After partial pressure of oxygen reaches more than the 90kPa, behind pyrogen test, be prepared into the osmotic diurtc composite electrolyte injection that contains hyperoxia.
2. a preparation method that contains electrolytical osmotic diuresis remover liquid injection is characterized in that, may further comprise the steps at least:
(1) in infusion solutions is produced, makes biomedical electrolysis matter injection by the medical use liquid routine operation, as base fluid;
(2) saturating property diuretic powder is dissolved in the base fluid, makes osmotic diurtc composite electrolyte injection.
3. the preparation method that contains hyperoxia and electrolytical osmotic diuresis remover liquid injection as claimed in claim 1, it is characterized in that, described biomedical electrolysis matter injection is to contain calcium chloride 0.01～0.03g in every 100ml liquid, potassium chloride 0.01～0.05g, sodium chloride 0.2～0.8g, sodium lactate 0.1～0.5g.
4. the preparation method that contains electrolytical osmotic diuresis remover liquid injection as claimed in claim 2, it is characterized in that described biomedical electrolysis matter injection is to contain calcium chloride 0.01～0.03g in every 100ml liquid, potassium chloride 0.01～0.05g, sodium chloride 0.2～0.8g, sodium lactate 0.1～0.5g.
5. the preparation method that contains hyperoxia and electrolytical osmotic diuresis remover liquid injection as claimed in claim 1, it is characterized in that, described osmotic diuretic is mannitol, piracetam, aniracetam, 1,6-fructose diphosphate, sorbitol, carbamide, glycerol one of them, or be the compound recipe of the osmotic diuretic of above-mentioned different proportion.
6. the preparation method that contains electrolytical osmotic diuresis remover liquid injection as claimed in claim 2, it is characterized in that, described osmotic diuretic is mannitol, piracetam, aniracetam, 1,6-fructose diphosphate, sorbitol, carbamide, glycerol one of them, or be the compound recipe of the osmotic diuretic of above-mentioned different proportion.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100086884A CN102078297A (en) | 2011-01-17 | 2011-01-17 | Method for preparing osmotic diuretic injection containing high oxygen or electrolyte |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100086884A CN102078297A (en) | 2011-01-17 | 2011-01-17 | Method for preparing osmotic diuretic injection containing high oxygen or electrolyte |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102078297A true CN102078297A (en) | 2011-06-01 |
Family
ID=44084626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011100086884A Pending CN102078297A (en) | 2011-01-17 | 2011-01-17 | Method for preparing osmotic diuretic injection containing high oxygen or electrolyte |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102078297A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102836170A (en) * | 2012-08-23 | 2012-12-26 | 徐礼鲜 | Hyperoxia compound glycine pyridoxal electrolyte injecta |
| CN104814955A (en) * | 2015-04-09 | 2015-08-05 | 山东罗欣药业集团股份有限公司 | Pharmaceutical composition for treating encephaledema |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1261000A (en) * | 1999-12-03 | 2000-07-26 | 邢军 | Medical oxygen-enriched liquid and oxygen-dissolving apparatus |
| CN1462616A (en) * | 2003-06-23 | 2003-12-24 | 徐礼鲜 | Method of preparing medical use injection containing high oxygen |
| CN1579417A (en) * | 2004-05-19 | 2005-02-16 | 杨希军 | Compound dewatered diuretic medicinal composition and its preparation method |
| CN1957917A (en) * | 2006-10-09 | 2007-05-09 | 中国人民解放军第四军医大学 | Method for preparing high oxygen large transfusion fluid |
-
2011
- 2011-01-17 CN CN2011100086884A patent/CN102078297A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1261000A (en) * | 1999-12-03 | 2000-07-26 | 邢军 | Medical oxygen-enriched liquid and oxygen-dissolving apparatus |
| CN1462616A (en) * | 2003-06-23 | 2003-12-24 | 徐礼鲜 | Method of preparing medical use injection containing high oxygen |
| CN1579417A (en) * | 2004-05-19 | 2005-02-16 | 杨希军 | Compound dewatered diuretic medicinal composition and its preparation method |
| CN1957917A (en) * | 2006-10-09 | 2007-05-09 | 中国人民解放军第四军医大学 | Method for preparing high oxygen large transfusion fluid |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102836170A (en) * | 2012-08-23 | 2012-12-26 | 徐礼鲜 | Hyperoxia compound glycine pyridoxal electrolyte injecta |
| CN104814955A (en) * | 2015-04-09 | 2015-08-05 | 山东罗欣药业集团股份有限公司 | Pharmaceutical composition for treating encephaledema |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102747403B (en) | Method of preparing magnesium-doped hydroxyapatite/titania active film on surface of medical titanium alloy | |
| CN101485683A (en) | Low-sodium peritoneal dialysis liquid | |
| CN101991589A (en) | Glycerol fructose injection and preparation method thereof | |
| CN101167740B (en) | Compound sodium acetate electrolyte injection and preparation method thereof | |
| CN104224829A (en) | Injection containing sodium, potassium, magnesium, calcium and glucose injection and preparation method of injection | |
| CN102078297A (en) | Method for preparing osmotic diuretic injection containing high oxygen or electrolyte | |
| CN103393715B (en) | Sodium potassium magnesium calcium and glucose injection and preparation method thereof | |
| CN107414992A (en) | A kind of processing technology of handicraft bamboo chip | |
| JP2015205864A (en) | Inhalation type pharmaceutical composition for treating gout and preparation method thereof | |
| ES2636637T3 (en) | Mixtures of starch derivatives | |
| CN101444526B (en) | Pharmaceutical composition | |
| CN102524242B (en) | Preparation method of organ preservation solution | |
| CN105476934A (en) | Mask of which deionized water solvent is replaced with peony hydrosol and preparation method of mask | |
| JP2015183006A (en) | Inhalation pharmaceutical composition for treating heart disease and method of preparation thereof | |
| CN104306396A (en) | Hydroxyethyl starch 130 sodium lactate ringer injection and preparation method thereof | |
| CN106659677A (en) | Universal cardioplegic solution (variants) | |
| CN106309481A (en) | Compound potassium aspartate-glucose injection and preparation method thereof | |
| TWI594772B (en) | Inhalation-type pharmaceutical composition for hypertension and preparation method thereof | |
| CN101375847A (en) | Medicament composition with dehydration and diuresis functions | |
| CN102397290B (en) | Hydroxyethyl starch injection and preparation method thereof | |
| AU2015317229A1 (en) | Dialysis solution | |
| CN104644668A (en) | First-aid plasma substitute medicine composition and preparation method thereof | |
| KR100893203B1 (en) | Pharmaceurtic Complex Using Distilled Water Comprising Bamboo salt | |
| CN104739852B (en) | A kind of Medical washing glue and preparation method thereof | |
| CN103385883B (en) | Pharmaceutical composition containing tropisetron hydrochloride and fructose |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20110601 |